Global MarketsIMPORTANT
Novo Nordisk (NOVOB DC) Q2 (DKK): Adj. EBIT 33.4bln (exp. 28.9bln), raises 2026 adj. sales and operating profit outlook to between 0% to -6% at CER (exp. -5.9%)
StockNow breaking-news AI analysis
Novo Nordisk beat Q2 adjusted EBIT expectations and raised its 2026 outlook, driven by strong GLP-1 and Wegovy pill sales despite ongoing competitive and pricing pressures.
News detail
Q2 2026 adj sales up 7% at CER; adj operating profit up 11% at CER. Improved outlook is driven by increased expectations for GLP-1 product sales.
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.